Manufacturer of Controlled Substances; Notice of Registration; Boehringer Ingelheim Chemicals, Inc., 64018-64019 [2013-25096]
Download as PDF
<![CDATA[
64018
Federal Register / Vol. 78, No. 207 / Friday, October 25, 2013 / Notices
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Application; GE
Healthcare
Pursuant to § 1301.33(a), Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on September 12,
2013, GE Healthcare, 3350 North Ridge
Avenue, Arlington Heights, Illinois
60004–1412, made application by
renewal to the Drug Enforcement
Administration (DEA) to be registered as
a bulk manufacturer of Cocaine (9041),
a basic class of controlled substance
listed in schedule II.
The company plans to manufacture a
radioactive product to diagnose
Parkinson’s disease for distribution to
its customers.
Any other such applicant, and any
person who is presently registered with
DEA to manufacture such a substance,
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections should be addressed, in
quintuplicate, to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODW), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than December 24, 2013.
Dated: October 16, 2013.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2013–25101 Filed 10–24–13; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
emcdonald on DSK67QTVN1PROD with NOTICES
Manufacturer of Controlled
Substances, Notice of Application,
Stepan Company
Pursuant to § 1301.33(a), Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on February 7, 2013,
Stepan Company, Natural Products
Dept., 100 W. Hunter Avenue,
Maywood, New Jersey 07607, made
application by renewal to the Drug
Enforcement Administration (DEA) to
be registered as a bulk manufacturer of
the following basic classes of controlled
substances:
Drug
Schedule
Cocaine (9041) .............................
Ecgonine (9180) ...........................
VerDate Mar<15>2010
17:55 Oct 24, 2013
II
II
Jkt 232001
The company plans to manufacture
the listed controlled substances in bulk
for distribution to their customers.
Any other such applicant, and any
person who is presently registered with
DEA to manufacture such substances,
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections should be addressed, in
quintuplicate, to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODW), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than December 24, 2013.
Dated: October 9, 2013.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2013–25097 Filed 10–24–13; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances, Notice of Application,
Research Triangle Institute
Pursuant to § 1301.33(a), Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on July 25, 2013,
Research Triangle Institute, Hermann
Building East Institute Drive, P.O. Box
12194, Research Triangle Park, North
Carolina 27709, made application by
letter to the Drug Enforcement
Administration (DEA) to be registered as
a bulk manufacturer of
Tetrahydrocannabinols (7370), a class of
controlled substance listed in schedule
I.
The company plans to provide small
quantities to commercial customers for
use in preparing test kits, reagents, and
reference standards.
The company plans to bulk
manufacture a synthetic
Tetrahydrocannabinol. No other activity
for this drug code is authorized for this
registration.
Any other such applicant, and any
person who is presently registered with
DEA to manufacture such substances,
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections should be addressed, in
quintuplicate, to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODW), 8701 Morrissette Drive,
PO 00000
Frm 00060
Fmt 4703
Sfmt 4703
Springfield, Virginia 22152; and must be
filed no later than December 24, 2013.
Dated: October 10, 2013.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2013–25085 Filed 10–24–13; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances, Notice of Application,
Nektar Therapeutics
Pursuant to § 1301.33(a), Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on August 16, 2013,
Nektar Therapeutics, 1112 Church
Street, Huntsville, Alabama 35801,
made application by renewal to the
Drug Enforcement Administration
(DEA) to be registered as a bulk
manufacturer of Fentanyl (9801), a basic
class of controlled substance listed in
schedule II.
The company plans to manufacture
the listed controlled substance in
support of product development.
Any other such applicant, and any
person who is presently registered with
DEA to manufacture such substances,
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections should be addressed, in
quintuplicate, to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODW), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than December 24, 2013.
Dated: September 27, 2013.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2013–25079 Filed 10–24–13; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Registration;
Boehringer Ingelheim Chemicals, Inc.
By Notice dated June 18, 2013, and
published in the Federal Register on
July 1, 2013, 78 FR 39340, Boehringer
Ingelheim Chemicals, Inc., 2820 N.
Normandy Drive, Petersburg, Virginia
23805–9372, made application by
E:\FR\FM\25OCN1.SGM
25OCN1
Federal Register / Vol. 78, No. 207 / Friday, October 25, 2013 / Notices
renewal to the Drug Enforcement
Administration (DEA) to be registered as
a bulk manufacturer of the following
basic classes of controlled substances:
Drug
Schedule
Methylphenidate (1724) ................
Methadone (9250) ........................
Methadone Intermediate (9254) ...
Tapentadol (9780) ........................
II
II
II
II
The company plans to manufacture
the listed controlled substances in bulk
for sale to its customers and formulation
into finished pharmaceuticals. In
reference to Methadone Intermediate
(9254) the company plans to produce
Methadone HCL active pharmaceutical
ingredients (APIs) for sale to its
customers.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and
determined that the registration of
Boehringer Ingelheim Chemicals, Inc.,
to manufacture the listed basic classes
of controlled substances is consistent
with the public interest at this time.
DEA has investigated Boehringer
Ingelheim Chemicals, Inc., to ensure
that the company’s registration is
consistent with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems; verification of the
company’s compliance with state and
local laws; and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C.
823(a), and in accordance with 21 CFR
1301.33, the above named company is
granted registration as a bulk
manufacturer of the basic classes of
controlled substances listed.
Dated: October, 16 2013.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
Drug Enforcement Administration
emcdonald on DSK67QTVN1PROD with NOTICES
Manufacturer of Controlled
Substances, Notice of Registration,
Austin Pharma, LLC.
By Notice dated May 14, 2013, and
published in the Federal Register on
May 22, 2013, 78 FR 30332, Austin
Pharma, LLC., 811 Paloma Drive, Suite
C, Round Rock, Texas 78665–2402,
made application by renewal to the
Drug Enforcement Administration
(DEA) to be registered as a bulk
Jkt 232001
Dated: October 10, 2013.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
DEPARTMENT OF JUSTICE
[FR Doc. 2013–25072 Filed 10–24–13; 8:45 am]
BILLING CODE 4410–09–P
Manufacturer of Controlled
Substances; Notice of Registration;
Agilent Technologies
DEPARTMENT OF JUSTICE
18:57 Oct 24, 2013
The company plans to manufacture
small quantities of the listed controlled
substances for use in diagnostic
products.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and
determined that the registration of
Agilent Technologies to manufacture
the listed basic classes of controlled
substances is consistent with the public
interest at this time. DEA has
investigated Agilent Technologies to
ensure that the company’s registration is
consistent with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with state and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 823(a),
and in accordance with 21 CFR 1301.33,
the above named company is granted
registration as a bulk manufacturer of
the basic classes of controlled
substances listed.
Drug Enforcement Administration
BILLING CODE 4410–09–P
VerDate Mar<15>2010
manufacturer of Tetrahydrocannabinols
(7370), a basic class of controlled
substance listed in schedule I.
The company plans to bulk
manufacture a synthetic
Tetrahydrocannabinol. No other activity
for this drug code is authorized for this
registration.
On August 9, 2013, Austin Pharma,
LLC., withdrew their request for the
addition of marihuana (7360) to their
registration.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and
determined that the registration of
Austin Pharma, LLC., to manufacture
the listed basic class of controlled
substance is consistent with the public
interest at this time. DEA has
investigated Austin Pharma, LLC., to
ensure that the company’s registration is
consistent with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with state and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 823,
and in accordance with 21 CFR 1301.33,
the above named company is granted
registration as a bulk manufacturer of
the basic class of controlled substance
listed.
DEPARTMENT OF JUSTICE
[FR Doc. 2013–25096 Filed 10–24–13; 8:45 am]
64019
By Notice dated May 24, 2013, and
published in the Federal Register on
June 4, 2013, 78 FR 33441, Agilent
Technologies, 25200 Commercentre
Drive, Lake Forest, California 92630–
8810, made application by renewal to
the Drug Enforcement Administration
(DEA) to be registered as a bulk
manufacturer of the following basic
classes of controlled substances:
Drug
Schedule
1-Piperidinocyclohexanecarbonitrile (8603).
Benzoylecgonine (9180) ...............
PO 00000
Frm 00061
Fmt 4703
Sfmt 4703
II
II
Dated: October 10, 2013.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2013–25078 Filed 10–24–13; 8:45 am]
BILLING CODE 4410–09–P
Drug Enforcement Administration
Manufacturer of Controlled
Substances, Notice of Registration,
Penick Corporation
By Notice dated May 24, 2013, and
published in the Federal Register on
June 4, 2013, 78 FR 33441, Penick
Corporation, 33 Industrial Park Road,
Pennsville, New Jersey 08070, made
application to the Drug Enforcement
Administration (DEA) to be registered as
a bulk manufacturer of Opium Tincture
(9630), a basic class of controlled
substance listed in schedule II.
The company plans to manufacture
the listed controlled substance, as bulk
intermediates for distribution to its
customers.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and
determined that the registration of
Penick Corporation to manufacture the
listed basic class of controlled substance
is consistent with the public interest at
this time. DEA has investigated Penick
Corporation to ensure that the
company’s registration is consistent
with the public interest. The
E:\FR\FM\25OCN1.SGM
25OCN1
]]>Agencies
[Federal Register Volume 78, Number 207 (Friday, October 25, 2013)]
[Notices]
[Pages 64018-64019]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2013-25096]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled Substances; Notice of Registration;
Boehringer Ingelheim Chemicals, Inc.
By Notice dated June 18, 2013, and published in the Federal
Register on July 1, 2013, 78 FR 39340, Boehringer Ingelheim Chemicals,
Inc., 2820 N. Normandy Drive, Petersburg, Virginia 23805-9372, made
application by
[[Page 64019]]
renewal to the Drug Enforcement Administration (DEA) to be registered
as a bulk manufacturer of the following basic classes of controlled
substances:
------------------------------------------------------------------------
Drug Schedule
------------------------------------------------------------------------
Methylphenidate (1724)..................... II
Methadone (9250)........................... II
Methadone Intermediate (9254).............. II
Tapentadol (9780).......................... II
------------------------------------------------------------------------
The company plans to manufacture the listed controlled substances
in bulk for sale to its customers and formulation into finished
pharmaceuticals. In reference to Methadone Intermediate (9254) the
company plans to produce Methadone HCL active pharmaceutical
ingredients (APIs) for sale to its customers.
No comments or objections have been received. DEA has considered
the factors in 21 U.S.C. 823(a) and determined that the registration of
Boehringer Ingelheim Chemicals, Inc., to manufacture the listed basic
classes of controlled substances is consistent with the public interest
at this time. DEA has investigated Boehringer Ingelheim Chemicals,
Inc., to ensure that the company's registration is consistent with the
public interest. The investigation has included inspection and testing
of the company's physical security systems; verification of the
company's compliance with state and local laws; and a review of the
company's background and history.
Therefore, pursuant to 21 U.S.C. 823(a), and in accordance with 21
CFR 1301.33, the above named company is granted registration as a bulk
manufacturer of the basic classes of controlled substances listed.
Dated: October, 16 2013.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. 2013-25096 Filed 10-24-13; 8:45 am]
BILLING CODE 4410-09-P
